---
title: "Musculoskeletal Pathology"
order: 6
category: "Systemic Pathology"
---

# Musculoskeletal Pathology

## Overview

Musculoskeletal pathology encompasses diseases of bones, joints, muscles, tendons, and ligaments. These disorders range from metabolic bone diseases and inflammatory arthropathies to neoplasms and represent major causes of morbidity, disability, and decreased quality of life.

### Epidemiology
- **Osteoarthritis**: Most common joint disease, affects >50% of population >65 years
- **Osteoporosis**: Affects 10 million Americans, 200 million worldwide
- **Rheumatoid arthritis**: Affects 1% of population, women > men (3:1)
- **Bone tumors**: Rare (<0.2% of cancers), but significant morbidity in young patients

## Bone Physiology and Remodeling

### Bone Composition
- **Organic matrix** (35%): Type I collagen (90%), osteocalcin, osteonectin, bone sialoprotein
- **Inorganic mineral** (65%): Hydroxyapatite crystals [Ca₁₀(PO₄)₆(OH)₂]
- **Cells**: Osteoblasts, osteocytes, osteoclasts, bone lining cells

### Bone Cells

**Osteoblasts**:
- Synthesize organic matrix (osteoid)
- Regulate mineralization
- Origin: Mesenchymal stem cells
- Express alkaline phosphatase (marker)
- Regulate osteoclastogenesis (RANKL/OPG system)

**Osteocytes**:
- Mature osteoblasts embedded in bone matrix
- Mechanosensors (detect mechanical stress)
- Regulate bone remodeling
- Connected via canaliculi

**Osteoclasts**:
- Multinucleated cells (fusion of monocyte/macrophage lineage)
- Bone resorption
- Ruffled border, clear zone
- Secrete H⁺ (acidify resorption pit), cathepsin K (digest collagen)
- **RANK** receptor (activated by RANKL from osteoblasts)

### Bone Remodeling

**Continuous process**: Resorption followed by formation

**Steps**:
1. **Activation**: Osteoclast recruitment and differentiation
2. **Resorption**: Osteoclasts dissolve mineral and digest matrix (2-4 weeks)
3. **Reversal**: Transition from resorption to formation
4. **Formation**: Osteoblasts synthesize new matrix (3-4 months)
5. **Mineralization**: Hydroxyapatite crystal deposition

**Regulation**:
- **Systemic**: PTH, vitamin D, calcitonin, estrogen, growth hormone, thyroid hormone, glucocorticoids
- **Local**: RANKL/RANK/OPG, Wnt/β-catenin, BMPs, TGF-β
- **Mechanical**: Wolff's law (bone adapts to mechanical stress)

**Coupled process**: Balance between resorption and formation maintains bone mass

## Metabolic Bone Diseases

### Osteoporosis

#### Definition
Decreased bone mass and deterioration of microarchitecture leading to increased fracture risk.

**Diagnostic criteria** (WHO):
- T-score ≤ -2.5 (bone mineral density >2.5 SD below young adult mean)
- Osteopenia: T-score -1.0 to -2.5

#### Epidemiology
- Most common metabolic bone disease
- 10 million affected in US, 44 million with low bone mass
- **Postmenopausal women** most affected
- 1 in 2 women, 1 in 4 men >50 will have osteoporotic fracture

#### Classification

**Primary Osteoporosis**:

**Type I (Postmenopausal)**:
- Women ages 50-70
- **Estrogen deficiency** after menopause
- Accelerated bone loss (especially trabecular bone)
- Vertebral and distal radius (Colles') fractures

**Type II (Senile)**:
- Men and women >70 years
- Age-related bone loss
- Decreased osteoblast function
- Decreased calcium absorption
- Hip and vertebral fractures

**Secondary Osteoporosis**:
- **Endocrine**: Hyperparathyroidism, hyperthyroidism, Cushing syndrome, hypogonadism
- **Drugs**: Glucocorticoids (most common), heparin, anticonvulsants, chemotherapy
- **Malignancy**: Multiple myeloma
- **GI**: Malabsorption, inflammatory bowel disease
- **Immobilization**
- **Genetic**: Osteogenesis imperfecta

#### Pathogenesis

**Postmenopausal**:
- **Estrogen deficiency** → Increased osteoclast activity
- Mechanisms:
  - Increased RANKL expression
  - Decreased OPG (decoy receptor for RANKL)
  - Increased IL-1, IL-6, TNF-α
  - Net result: Increased bone resorption > formation
- Accelerated loss: 2-3% per year for 5-10 years after menopause

**Senile**:
- Decreased osteoblast function with age
- Decreased physical activity
- Decreased calcium absorption (intestine)
- Decreased vitamin D production (skin, kidney)
- Secondary hyperparathyroidism
- Increased PTH → bone resorption

#### Pathology

**Gross**:
- Thinned cortices
- Enlarged medullary cavity
- Decreased trabecular bone
- Vertebral compression fractures (wedge-shaped, "codfish" vertebrae)

**Microscopic**:
- **Decreased bone mass** (qualitatively normal bone)
- Thin cortices
- Thin, disconnected trabeculae
- Loss of trabecular connectivity
- Normal mineralization (distinguishes from osteomalacia)

#### Clinical Features
- Often asymptomatic until fracture
- **Fragility fractures** (low-energy trauma):
  - **Vertebral compression fractures** (most common): Kyphosis, loss of height, back pain
  - **Hip fractures** (femoral neck, intertrochanteric): High morbidity and mortality
  - **Distal radius fractures** (Colles' fracture)
  - Proximal humerus, pelvis

**Complications**:
- Chronic pain
- Disability
- Loss of independence
- Mortality (especially hip fractures: 20% 1-year mortality)

#### Diagnosis
- **DEXA scan** (dual-energy X-ray absorptiometry): Bone mineral density
  - Hip and lumbar spine
  - T-score: Comparison to young adult
- **FRAX**: 10-year fracture risk assessment
- **Biochemical markers**:
  - Calcium, phosphate: Normal
  - Alkaline phosphatase: Normal
  - PTH: Normal (unless secondary hyperparathyroidism)
  - 25-OH vitamin D: May be low

#### Prevention and Treatment

**Prevention**:
- Adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day)
- Weight-bearing exercise
- Fall prevention
- Smoking cessation
- Limit alcohol

**Pharmacologic**:

**Antiresorptive agents**:
- **Bisphosphonates**: Alendronate, risedronate, zoledronic acid (first-line)
  - Inhibit osteoclasts (induce apoptosis)
  - Reduce fracture risk 30-50%
  - Side effects: Osteonecrosis of jaw (rare), atypical femur fractures (rare)
- **Denosumab**: RANKL antibody (inhibits osteoclast formation)
- **Selective estrogen receptor modulators (SERMs)**: Raloxifene
- **Estrogen replacement therapy**: Not first-line (cardiovascular risks)

**Anabolic agents**:
- **Teriparatide**: Recombinant PTH (1-34)
  - Stimulates osteoblasts
  - Increases bone formation
  - Limited to 2 years (osteosarcoma risk in rats)
- **Romosozumab**: Sclerostin antibody (activates Wnt pathway)

### Osteomalacia and Rickets

#### Definition
Defective mineralization of bone matrix (osteoid).

- **Rickets**: Occurs in children (before epiphyseal closure)
- **Osteomalacia**: Occurs in adults (after epiphyseal closure)

#### Etiology

**Vitamin D deficiency** (most common):
- Dietary insufficiency
- Inadequate sun exposure
- Malabsorption (celiac disease, IBD, bariatric surgery)
- Liver disease (decreased 25-hydroxylation)
- Chronic kidney disease (decreased 1α-hydroxylation)

**Phosphate deficiency**:
- Dietary (rare)
- Renal phosphate wasting:
  - X-linked hypophosphatemia (PHEX mutation)
  - Tumor-induced osteomalacia (FGF23 production)
  - Fanconi syndrome

**Impaired mineralization**:
- Hypophosphatasia (alkaline phosphatase deficiency)
- Chronic renal failure (renal osteodystrophy)
- Aluminum toxicity (dialysis patients, historical)

#### Pathogenesis

**Vitamin D metabolism**:
1. Vitamin D₃ (cholecalciferol) from skin (UV) or diet
2. **25-hydroxylation** in liver → 25-OH-D (calcidiol)
3. **1α-hydroxylation** in kidney → 1,25-(OH)₂-D (calcitriol, active form)

**Vitamin D deficiency** → Decreased intestinal calcium and phosphate absorption → Hypocalcemia and hypophosphatemia → Secondary hyperparathyroidism → Increased bone resorption, increased renal phosphate excretion → Further hypophosphatemia → **Defective mineralization**

#### Pathology

**Rickets**:
- **Widened growth plate** (unmineralized cartilage)
- Irregular, enlarged costochondral junctions (**rachitic rosary**)
- Bowing of long bones (weight-bearing deformities)
- Delayed fontanelle closure, craniotabes (soft skull)

**Osteomalacia**:
- **Increased osteoid** (unmineralized matrix)
- **Wide osteoid seams** (>12-15 μm)
- Decreased mineralization (tetracycline labeling shows decreased uptake)
- **Looser zones (pseudofractures)**: Radiolucent bands, perpendicular to cortex
  - Femoral neck, pubic rami, scapula, ribs
  - Insufficiency fractures

**Microscopy** (hallmark):
- **Increased osteoid volume** (>10%)
- **Widened osteoid seams** (>15 μm)
- Delayed mineralization lag time
- Normal bone architecture

#### Clinical Features

**Rickets**:
- Skeletal deformities (bowing, knock-knees, pigeon chest)
- Rachitic rosary (beading at costochondral junctions)
- Craniotabes
- Delayed motor development
- Hypocalcemic tetany, seizures

**Osteomalacia**:
- **Bone pain** (diffuse, worse with weight-bearing)
- **Muscle weakness** (proximal myopathy)
- Fractures (vertebral, hip, pelvis)
- Waddling gait

#### Laboratory

**Vitamin D deficiency**:
- Low 25-OH vitamin D (<20 ng/mL)
- Low or normal calcium
- Low phosphate
- Elevated PTH (secondary hyperparathyroidism)
- **Elevated alkaline phosphatase** (increased bone turnover)
- Low 1,25-(OH)₂-D (in chronic kidney disease)

#### Treatment
- **Vitamin D supplementation**:
  - Ergocalciferol (D₂) or cholecalciferol (D₃)
  - High doses initially, then maintenance
- **Calcium supplementation**
- Treat underlying cause
- **Calcitriol** (1,25-(OH)₂-D) if renal failure

### Paget's Disease of Bone

#### Definition
Chronic disorder characterized by excessive bone remodeling with abnormal architecture.

#### Epidemiology
- Prevalence increases with age (>40 years)
- More common in Anglo-Saxons (UK, US, Australia)
- Men = Women
- Often asymptomatic (discovered incidentally)

#### Etiology
- Unknown
- **Genetic component**: 15-30% familial
  - **SQSTM1 (p62) mutations**
- **Viral hypothesis**: Paramyxovirus (measles, respiratory syncytial virus) - controversial

#### Pathogenesis
1. **Osteoclastic phase**: Abnormal osteoclasts with increased resorption
   - Osteoclasts are larger, have more nuclei (up to 100)
2. **Mixed phase**: Increased osteoblast activity (coupling)
3. **Osteoblastic (sclerotic) phase**: Predominant bone formation
   - Disorganized bone formation (woven bone)

**Result**: Mosaic pattern of lamellar bone (jigsaw puzzle appearance)

#### Pathology

**Gross**:
- Thickened, enlarged bones
- Cortical thickening
- Coarse, irregular trabecular pattern

**Microscopic**:
- **Mosaic pattern**: Hallmark
  - Irregular cement lines (jigsaw puzzle)
  - Chaotic arrangement of lamellar bone
- **Woven bone** in active phase
- Numerous prominent osteoclasts (>20 nuclei)
- Fibrovascular marrow replacement (active phase)

**Sites**:
- **Pelvis** (70%)
- **Spine** (50%)
- **Femur** (55%)
- **Skull** (40%)
- Tibia
- Usually polyostotic (affects multiple bones)

#### Clinical Features
- **Often asymptomatic** (70-90%)
- **Bone pain** (deep, aching)
- **Skeletal deformities**:
  - Bowing of femur and tibia (anterior, lateral)
  - Enlargement of skull (hat size increases)
- **Fractures**: "Banana" or chalk-stick fractures
- **Neurological complications**:
  - Nerve compression (cranial nerves, spinal stenosis)
  - Hearing loss (CN VIII compression, otosclerosis)
- **High-output cardiac failure**: Increased blood flow through bone (extensive disease)
- **Hypercalcemia**: Immobilization

#### Laboratory
- **Markedly elevated alkaline phosphatase** (reflects increased bone turnover)
  - Can be 10-20× normal
- Normal calcium, phosphate, PTH
- Elevated urinary hydroxyproline (bone resorption marker)

#### Complications
- **Pathologic fractures**
- **Osteoarthritis** (secondary, in adjacent joints)
- **Osteosarcoma** (rare, <1%): Most serious
  - Older patients, rapid growth, pain
  - Poor prognosis

#### Treatment
- **Bisphosphonates**: Suppress osteoclastic activity
  - Alendronate, risedronate, zoledronic acid
  - Normalize alkaline phosphatase, relieve pain
- **Calcitonin**: Inhibits osteoclasts (second-line)
- Analgesics for pain
- Surgery for complications (fractures, arthritis, deformities)

## Inflammatory Arthropathies

### Rheumatoid Arthritis (RA)

#### Definition
Chronic systemic autoimmune disease characterized by inflammatory synovitis, primarily affecting peripheral joints.

#### Epidemiology
- Prevalence: 0.5-1% of population
- **Women > men** (3:1)
- Peak onset: 40-60 years
- Can occur at any age (juvenile idiopathic arthritis in children)

#### Etiology and Pathogenesis

**Genetic susceptibility**:
- **HLA-DR4** (DRB1*04:01, DRB1*04:04): Strongest association
- **Shared epitope**: Conserved amino acid sequence in HLA-DRB1
- Other genes: PTPN22, STAT4, TRAF1, TNFAIP3

**Environmental triggers**:
- Smoking (strongest environmental risk)
- Infections (EBV, P. gingivalis)
- Microbiome alterations

**Autoimmunity**:
- **Citrullinated proteins**: Post-translational modification (arginine → citrulline)
  - Smoking, inflammation increase citrullination
  - Altered self-antigens
- **Autoantibodies**:
  - **Anti-CCP** (anti-cyclic citrullinated peptide): Highly specific (95%), 60-70% sensitive
  - **Rheumatoid factor (RF)**: IgM against Fc portion of IgG (70-80% of RA)
    - Not specific (also in other diseases, elderly)

**Immune response**:
- CD4+ T cells (Th1, Th17) activated
- B cells produce autoantibodies
- Macrophages activated
- **Synovitis**: Inflammation of synovial membrane

**Pannus formation**:
- Proliferative, invasive synovial tissue
- Granulation tissue with inflammatory cells
- Erodes cartilage and bone

**Cytokines**:
- **TNF-α**: Key mediator (target for therapy)
- IL-1, IL-6, IL-17
- Stimulate synoviocytes, osteoclasts, chondrocytes
- Cartilage and bone destruction

#### Pathology

**Gross**:
- **Symmetrical polyarthritis**: Small joints of hands and feet initially
  - MCPs, PIPs (DIP spared), wrists, MTPs
- Larger joints later (knees, ankles, elbows, shoulders)
- Synovial thickening
- Joint effusions
- Cartilage erosion, bone destruction
- Deformities:
  - **Ulnar deviation** of fingers
  - **Swan-neck deformity**: Hyperextension PIP, flexion DIP
  - **Boutonnière deformity**: Flexion PIP, hyperextension DIP
  - Subluxation, ankylosis

**Microscopic**:

**Synovitis**:
- **Synovial hyperplasia**: Villous projections
- **Inflammatory infiltrate**: Lymphocytes, plasma cells, macrophages
- **Lymphoid follicles** with germinal centers
- Increased vascularity
- Fibrin deposition

**Pannus**:
- Granulation tissue (fibroblasts, inflammatory cells, vessels)
- Invades and destroys cartilage and bone
- Interface between pannus and cartilage (erosion front)

**Rheumatoid nodules** (20-30% of patients):
- Subcutaneous nodules (extensor surfaces, pressure points)
- **Central fibrinoid necrosis**
- **Palisading histiocytes** (epithelioid macrophages) surrounding necrosis
- Peripheral chronic inflammation

#### Clinical Features

**Articular**:
- **Symmetrical polyarthritis**
- Morning stiffness (>1 hour)
- Joint pain, swelling, tenderness
- Warmth, erythema (less than in septic arthritis)
- Progressive joint destruction
- Deformities, disability

**Extra-articular** (25% of patients):
- **Rheumatoid nodules**: Subcutaneous (elbows, fingers, Achilles tendon)
- **Pulmonary**:
  - Interstitial lung disease (ILD): Usual interstitial pneumonia pattern
  - Pleural effusion, pleuritis
  - Pulmonary nodules (can cavitate)
  - Caplan syndrome: RA + pneumoconiosis
- **Cardiac**:
  - Pericarditis (most common cardiac manifestation)
  - Myocarditis, valvular disease
- **Ocular**:
  - Keratoconjunctivitis sicca (Sjögren's syndrome overlap)
  - Episcleritis, scleritis
- **Vasculitis**: Small-medium vessel (severe disease)
- **Felty syndrome**: RA + splenomegaly + neutropenia
- **Increased cardiovascular risk**: Accelerated atherosclerosis

#### Laboratory and Imaging

**Serology**:
- **Rheumatoid factor (RF)**: Positive in 70-80%
- **Anti-CCP**: Positive in 60-70%, highly specific
- Elevated ESR, CRP (inflammation)
- Anemia of chronic disease

**Synovial fluid**:
- Inflammatory: WBC 2,000-50,000/μL (predominantly neutrophils)
- Decreased viscosity, cloudy
- No crystals (vs. gout, pseudogout)

**Imaging**:
- **X-ray**:
  - Soft tissue swelling (early)
  - Periarticular osteopenia (juxta-articular)
  - **Marginal erosions** (diagnostic)
  - Joint space narrowing
  - Subluxation, ankylosis (late)
- **MRI/Ultrasound**: Detect synovitis, erosions earlier

#### Diagnosis
**2010 ACR/EULAR Classification Criteria** (score ≥6/10):
- Joint involvement (0-5 points)
- Serology: RF and/or anti-CCP (0-3 points)
- Acute phase reactants: ESR and/or CRP (0-1 point)
- Duration ≥6 weeks (1 point)

#### Treatment

**Goals**: Reduce inflammation, prevent joint damage, maintain function

**DMARDs** (Disease-Modifying Anti-Rheumatic Drugs):
- **Methotrexate**: First-line
- Hydroxychloroquine, sulfasalazine, leflunomide

**Biologic DMARDs**:
- **Anti-TNF**: Infliximab, etanercept, adalimumab, golimumab, certolizumab
- **Anti-IL-6**: Tocilizumab, sarilumab
- **Anti-CD20 (B-cell)**: Rituximab
- **CTLA-4-Ig (T-cell)**: Abatacept
- **JAK inhibitors**: Tofacitinib, baricitinib, upadacitinib

**NSAIDs and Glucocorticoids**: Symptomatic relief

**Surgery**: Joint replacement (severe disease)

#### Prognosis
- Chronic, progressive disease
- Variable course
- Aggressive treatment improves outcomes (prevent joint damage)
- Increased mortality (cardiovascular disease, infections)

### Seronegative Spondyloarthropathies

**Group of related inflammatory arthritides**:
- Ankylosing spondylitis
- Psoriatic arthritis
- Reactive arthritis (Reiter's syndrome)
- Enteropathic arthritis (IBD-associated)

**Shared features**:
- **Seronegativity**: Negative rheumatoid factor
- **HLA-B27 association** (strong)
- **Axial arthritis**: Sacroiliitis, spondylitis
- **Asymmetric oligoarthritis**: Lower extremities
- **Enthesitis**: Inflammation at tendon/ligament insertions (Achilles, plantar fascia)
- **Extra-articular**: Uveitis, aortitis, skin/mucosal lesions

#### Ankylosing Spondylitis (AS)

**Chronic inflammatory disease of spine and sacroiliac joints**

**Epidemiology**:
- Prevalence: 0.2-0.5%
- Men > women (3:1)
- Age of onset: 20-30 years
- **HLA-B27 positive** in 90-95%

**Pathology**:
- **Sacroiliitis**: Erosions, sclerosis, fusion (bilateral, symmetric)
- **Spondylitis**: Ascending inflammation of spine
- **Syndesmophytes**: Vertical bony bridges between vertebrae (ossification of annulus fibrosus)
- **"Bamboo spine"**: Fused vertebral column (late)
- Erosions at vertebral margins (Romanus lesions)
- Enthesitis

**Clinical**:
- **Low back pain and stiffness**: Insidious onset, improves with activity, worse at rest
- Morning stiffness (>30 minutes)
- Limited spinal mobility (Schober test)
- Loss of lumbar lordosis, increased kyphosis
- Reduced chest expansion (costovertebral joints)
- **Extra-articular**:
  - Anterior uveitis (25-30%)
  - Aortic insufficiency, heart block
  - Apical pulmonary fibrosis

**Treatment**: NSAIDs, TNF inhibitors, IL-17 inhibitors, physical therapy

### Gout

#### Definition
Crystal arthropathy caused by deposition of monosodium urate (MSU) crystals in joints and soft tissues.

#### Epidemiology
- Prevalence: 3-6% in men, 1-2% in women
- Men >> women (9:1) until menopause
- Age >40 years (men), postmenopausal (women)
- Increasing prevalence (obesity, diet)

#### Pathogenesis

**Hyperuricemia** (prerequisite, but not sufficient):
- Serum urate >6.8 mg/dL (saturation point)
- Only 10-20% of hyperuricemic individuals develop gout

**Causes of hyperuricemia**:

**Increased production**:
- **Diet**: High purine (red meat, seafood, alcohol - especially beer)
- **Increased cell turnover**: Leukemia, lymphoma, psoriasis, chemotherapy (tumor lysis syndrome)
- **Enzyme defects**: HGPRT deficiency (Lesch-Nyhan syndrome), PRPP synthetase overactivity

**Decreased excretion** (90% of cases):
- **Renal insufficiency**
- **Drugs**: Thiazide and loop diuretics (most common), low-dose aspirin, cyclosporine
- **Dehydration, acidosis**
- Genetic (SLC22A12, ABCG2 polymorphisms)

**Crystal formation**:
- Hyperuricemia → MSU crystal precipitation in joints
- Triggered by: Trauma, temperature change, pH change

**Inflammatory response**:
1. MSU crystals phagocytosed by neutrophils
2. NLRP3 inflammasome activation
3. IL-1β release
4. Neutrophil influx
5. **Acute gouty arthritis**

#### Pathology

**Gross**:
- **Tophi**: Chalky white deposits of urate crystals
  - Joints, soft tissues, cartilage, bone
  - Extensor surfaces, ears, Achilles tendon, fingers
- Joint erosions (chronic gout)

**Microscopic**:
- **MSU crystals**:
  - **Needle-shaped**
  - **Negatively birefringent** under polarized light (yellow when parallel to polarizer axis)
  - Dissolved by formalin fixation (need alcohol fixation or frozen section)
- **Acute inflammation**: Neutrophilic infiltrate
- **Tophi**:
  - Amorphous urate deposits (appear empty if fixed in formalin)
  - Foreign body giant cells
  - Chronic inflammation

**Synovial fluid**:
- Inflammatory: WBC 20,000-100,000/μL (neutrophils)
- **MSU crystals** (diagnostic): Intracellular (in neutrophils) and extracellular

#### Clinical Features

**Acute gouty arthritis**:
- **Sudden onset** (often at night)
- **Severe pain**, swelling, erythema, warmth
- **First MTP joint** (podagra) - classic (50% of first attacks)
- Other joints: Ankle, knee, wrist, fingers
- Usually **monoarticular** (especially first attack)
- Symptoms peak 12-24 hours
- Self-limited (resolves in 1-2 weeks without treatment)
- Triggers: Alcohol, dehydration, trauma, surgery, diuretics

**Intercritical period**:
- Asymptomatic intervals between attacks
- Recurrent attacks (frequency increases over time)

**Chronic tophaceous gout**:
- Develops after years of recurrent attacks
- **Tophi**: Painless nodules (ears, fingers, elbows, Achilles)
- Chronic joint damage, deformities
- Secondary osteoarthritis

**Complications**:
- **Urate nephropathy**: Chronic interstitial nephritis, kidney stones
- **Kidney disease**: CKD (multifactorial)

#### Diagnosis
- **Clinical**: Acute monoarthritis (first MTP)
- **Synovial fluid analysis**: MSU crystals (gold standard)
- **Serum urate**: Elevated (but can be normal during acute attack)
- **Imaging**:
  - X-ray: Erosions with overhanging edge (chronic)
  - Dual-energy CT: Urate crystal deposition

#### Treatment

**Acute attack**:
- **NSAIDs**: First-line (indomethacin, naproxen)
- **Colchicine**: Inhibits neutrophil function (microtubule disruption)
- **Glucocorticoids**: If NSAIDs/colchicine contraindicated

**Urate-lowering therapy** (chronic management):
- Indications: Recurrent attacks, tophi, chronic gouty arthropathy, urate nephropathy
- **Xanthine oxidase inhibitors**:
  - **Allopurinol**: First-line (inhibits uric acid synthesis)
  - **Febuxostat**: Alternative
- **Uricosuric agents**: Probenecid (increases renal excretion)
- **Uricase**: Pegloticase (converts uric acid to allantoin)
- Target urate <6 mg/dL

**Prophylaxis during urate-lowering therapy**: Colchicine or NSAIDs (prevent flares)

**Lifestyle modifications**: Weight loss, limit alcohol, reduce purine intake, hydration

### Calcium Pyrophosphate Deposition Disease (CPPD) / Pseudogout

#### Definition
Crystal arthropathy caused by deposition of calcium pyrophosphate dihydrate (CPPD) crystals in cartilage and joints.

#### Epidemiology
- Increases with age (>60 years)
- Men = Women
- Associated with aging and joint damage

#### Pathogenesis
- Increased production or decreased degradation of inorganic pyrophosphate
- Crystal deposition in cartilage (**chondrocalcinosis**)
- Crystal shedding into joint → acute inflammation

**Associated conditions**:
- **Aging** (most common)
- **Hemochromatosis**
- **Hyperparathyroidism**
- **Hypothyroidism**
- **Hypomagnesemia**
- **Hypophosphatasia**
- **Familial** (rare)

#### Pathology

**Microscopic**:
- **CPPD crystals**:
  - **Rhomboid or rod-shaped**
  - **Weakly positively birefringent** (blue when parallel to polarizer)
  - Basophilic deposits in cartilage

**Synovial fluid**:
- Inflammatory (acute): WBC 10,000-50,000/μL
- **CPPD crystals** (intracellular and extracellular)

#### Clinical Features

**Acute CPP crystal arthritis** ("pseudogout"):
- Sudden onset of pain, swelling
- **Knee** most common (50%), also wrist, shoulder, ankle
- Usually **monoarticular**
- Mimics gout (hence "pseudogout")
- Self-limited (days to weeks)

**Chronic CPP crystal inflammatory arthritis**:
- Chronic inflammatory arthritis
- Mimics rheumatoid arthritis

**Osteoarthritis with CPPD**:
- Most common presentation
- OA in atypical joints (wrist, MCP, shoulder)

**Asymptomatic**:
- Chondrocalcinosis on imaging
- No symptoms

#### Diagnosis
- **Synovial fluid analysis**: CPPD crystals
- **X-ray**: **Chondrocalcinosis** (calcification of cartilage)
  - Knee (menisci), wrist (triangular fibrocartilage), symphysis pubis

#### Treatment
- **Acute**: NSAIDs, colchicine, glucocorticoid injection
- **Chronic**: NSAIDs, low-dose colchicine
- No urate-lowering equivalent (cannot dissolve CPPD deposits)
- Treat underlying conditions (hyperparathyroidism, etc.)

## Degenerative Joint Disease

### Osteoarthritis (OA)

#### Definition
Degenerative joint disease characterized by progressive erosion of articular cartilage, subchondral bone changes, and osteophyte formation.

#### Epidemiology
- **Most common joint disease**
- Affects >50% of population >65 years
- Leading cause of disability in elderly
- Women > men (especially after menopause)
- Universal with aging

#### Classification

**Primary (idiopathic) OA**:
- No identifiable predisposing factor
- Age-related
- **Hands** (DIP, PIP, first CMC), **knees**, **hips**, **spine**

**Secondary OA**:
- Known predisposing factor:
  - **Trauma** (fracture, meniscal tear, ligament injury)
  - **Congenital/developmental**: Hip dysplasia, Legg-Calvé-Perthes
  - **Metabolic**: Hemochromatosis, Wilson disease, ochronosis
  - **Inflammatory**: Prior septic arthritis, RA
  - **Crystal deposition**: Gout, CPPD
  - **Neuropathic (Charcot joint)**: Diabetes, syphilis (tabes dorsalis)
  - **Obesity**: Mechanical stress on weight-bearing joints

#### Pathogenesis

**Normal cartilage**:
- Avascular, aneural tissue
- Type II collagen, proteoglycans (aggrecan)
- Chondrocytes maintain matrix

**OA pathogenesis**:
1. **Initiating factors**: Aging, mechanical stress, injury
2. **Chondrocyte activation**: Release of degradative enzymes
   - Matrix metalloproteinases (MMPs, especially MMP-13)
   - Aggrecanases (ADAMTS)
3. **Cartilage degradation**: Loss of proteoglycans, collagen disruption
4. **Decreased matrix synthesis**: Chondrocyte senescence
5. **Cartilage fibrillation, fissuring, erosion**
6. **Subchondral bone changes**: Sclerosis, cysts, osteophytes
7. **Synovitis**: Secondary inflammation (not primary)

**Biomechanical factors**:
- Abnormal stress on normal cartilage (obesity, malalignment)
- Normal stress on abnormal cartilage (prior injury, genetic)

**Inflammatory mediators**:
- IL-1, TNF-α, prostaglandins (from synovium and chondrocytes)
- Low-grade inflammation

#### Pathology

**Gross**:
- **Cartilage loss**: Focal initially, progresses to full-thickness (eburnation - polished bone)
- **Osteophytes** (bone spurs): Marginal proliferations at joint edges
- **Subchondral sclerosis**: Increased bone density (eburnation)
- **Subchondral cysts**: Synovial fluid intrusion into bone
- Thickened joint capsule
- Mild synovial inflammation

**Microscopic**:
- **Cartilage**:
  - **Surface fibrillation** (shredding)
  - **Vertical fissures** (clefting)
  - **Loss of cartilage** (full thickness)
  - Chondrocyte clusters (attempt at repair)
  - Loss of proteoglycans
- **Subchondral bone**:
  - Sclerosis (increased trabecular bone)
  - Cysts with fibrous or myxoid tissue
  - Microfractures
- **Osteophytes**: Cartilage-capped bony outgrowths
- **Synovium**: Mild chronic inflammation (not prominent like RA)

#### Clinical Features

**Symptoms**:
- **Pain**: Worse with activity, relieved by rest (mechanical pain)
  - Later: Pain at rest, night pain
- **Stiffness**: Morning stiffness <30 minutes (vs. RA >1 hour), "gelling" after inactivity
- **Decreased range of motion**
- **Crepitus**: Grinding sensation with movement
- **Joint instability** (advanced)

**Signs**:
- **Joint enlargement**: Osteophytes, effusion
- **Bony enlargement**:
  - **Heberden's nodes**: DIP joints
  - **Bouchard's nodes**: PIP joints
- Reduced range of motion
- Malalignment (varus/valgus deformity)
- Gait abnormalities

**Distribution**:
- **Hands**: DIP >> PIP, first CMC (thumb base)
  - **DIP involvement** (vs. RA which spares DIP)
- **Knees** (most common large joint): Medial > lateral > patellofemoral
- **Hips**: Groin pain
- **Spine**: Cervical, lumbar (facet joints, disc degeneration)
  - Osteophytes → spinal stenosis, radiculopathy
- **Feet**: First MTP

**Systemic symptoms**: Absent (vs. RA)

#### Diagnosis
- **Clinical**: Based on symptoms, signs, imaging
- **X-ray** (classic features):
  - **Joint space narrowing** (asymmetric)
  - **Osteophytes**
  - **Subchondral sclerosis**
  - **Subchondral cysts**
  - "LOSS": Loss of joint space, Osteophytes, Subchondral sclerosis, Subchondral cysts
- **Laboratory**: Normal (ESR, CRP, RF, anti-CCP)
- **Synovial fluid**: Non-inflammatory (WBC <2,000/μL)

#### Treatment

**Non-pharmacologic**:
- **Weight loss** (if overweight): Decreases joint stress
- **Exercise**: Strengthen muscles, maintain ROM, low-impact (swimming, cycling)
- **Physical therapy**: Range of motion, strengthening
- **Assistive devices**: Cane, walker, braces
- **Heat/ice**

**Pharmacologic**:
- **Acetaminophen**: First-line for mild pain
- **NSAIDs**: Topical (first) or oral (moderate-severe pain)
  - Risks: GI bleeding, cardiovascular, renal
- **Intra-articular glucocorticoid injections**: Temporary relief (not >3-4 per year)
- **Duloxetine**: Chronic pain (SNRI)
- **Topical capsaicin**

**No disease-modifying agents** (glucosamine, chondroitin sulfate: No proven benefit)

**Surgical**:
- **Joint replacement** (arthroplasty): Severe, refractory pain, disability
  - Total knee replacement (TKR), total hip replacement (THR)
  - Excellent outcomes
- **Arthroscopic debridement**: Limited benefit
- **Osteotomy**: Realignment (younger patients, unicompartmental disease)

#### Prognosis
- Progressive, irreversible
- Variable rate of progression
- Disability in advanced cases
- Does not affect life expectancy

## Bone Neoplasms

### Overview

**Epidemiology**:
- **Rare**: <0.2% of all cancers
- **Bimodal age distribution**:
  - Children/young adults (10-25 years): Osteosarcoma, Ewing sarcoma
  - Elderly (>65 years): Chondrosarcoma, myeloma, metastases
- **Metastases to bone >> primary bone tumors** (20:1)

**Classification**:
- **Bone-forming**: Osteosarcoma, osteoblastoma, osteoid osteoma
- **Cartilage-forming**: Chondrosarcoma, enchondroma, osteochondroma
- **Fibrous**: Fibrous dysplasia, fibrosarcoma
- **Hematopoietic**: Multiple myeloma, lymphoma
- **Other**: Ewing sarcoma, giant cell tumor

### Benign Bone Tumors

#### Osteochondroma (Exostosis)

**Most common benign bone tumor**

**Epidemiology**: Children and adolescents, males > females

**Pathology**:
- Bony protrusion with cartilage cap (continuous with underlying bone)
- **Cartilage cap** <2 cm (>2 cm suggests malignancy)
- Medullary and cortical continuity with native bone
- Metaphysis of long bones (distal femur, proximal tibia, proximal humerus)

**Clinical**:
- Often asymptomatic (incidental)
- Painless mass
- Stops growing after skeletal maturity
- **Hereditary multiple exostoses**: Autosomal dominant, EXT1/EXT2 mutations, increased malignancy risk

**Malignant transformation**: Rare (<1%), to chondrosarcoma

#### Enchondroma

**Benign cartilage tumor within medullary cavity**

**Pathology**:
- Hyaline cartilage nodules
- Small bones of hands and feet (most common), also long bones (femur, humerus)
- Lobules of cartilage with small chondrocytes

**Clinical**:
- Usually asymptomatic
- May present with pathologic fracture
- **Ollier disease**: Multiple enchondromas (one extremity), increased malignancy risk
- **Maffucci syndrome**: Enchondromas + soft tissue hemangiomas, high malignancy risk

**Malignant transformation**: Rare in solitary, high in syndromes

#### Osteoid Osteoma

**Small, benign bone-forming tumor**

**Epidemiology**: Young adults (10-30 years), males > females (2:1)

**Pathology**:
- **Nidus** (<2 cm): Central radiolucency on imaging
- Surrounded by sclerotic bone (reactive)
- Microscopically: Woven bone and osteoid with osteoblasts, vascular stroma
- **Location**: Cortex of long bones (femur, tibia), posterior elements of spine

**Clinical**:
- **Nocturnal pain**: Worse at night, relieved by aspirin/NSAIDs (prostaglandin production)
- Point tenderness

**Treatment**: Excision or ablation, curative

**Osteoblastoma**: Larger (>2 cm), similar histology, spine common

#### Giant Cell Tumor of Bone

**Benign but locally aggressive**

**Epidemiology**: 20-40 years, women = men

**Pathology**:
- **Epiphysis** of long bones (distal femur, proximal tibia, distal radius)
- Extends to subarticular bone (abuts articular cartilage)
- **Multinucleated giant cells** (osteoclast-like) + mononuclear stromal cells
- Stromal cells are neoplastic (express RANKL)

**Clinical**:
- Pain, swelling
- Pathologic fracture
- "Soap bubble" appearance on X-ray (lytic, eccentric, no sclerotic rim)

**Behavior**:
- **Locally aggressive**: Erodes bone, extends into soft tissue
- **Recurrence**: 40-50% after curettage
- **Metastases**: Rare (2-5%), lungs ("benign metastases")

**Treatment**: Curettage ± adjuvant (phenol, cement), resection if extensive, denosumab (RANKL inhibitor)

### Malignant Bone Tumors

#### Osteosarcoma

**Most common primary malignant bone tumor** (excluding myeloma)

**Epidemiology**:
- **Bimodal age distribution**:
  - **Primary**: Adolescents (10-20 years, peak at growth spurt)
  - **Secondary**: Elderly (Paget's disease, radiation)
- Males > females (1.5:1)

**Etiology**:
- **Primary**: Sporadic
  - **RB1 mutations** (hereditary retinoblastoma patients: 1000× risk)
  - **TP53 mutations** (Li-Fraumeni syndrome)
- **Secondary**:
  - **Paget's disease** (<1% of Paget's patients, but most common cause of secondary osteosarcoma in elderly)
  - **Radiation**: Prior radiation therapy (latency 10-20 years)
  - **Bone infarcts**, fibrous dysplasia

**Pathology**:

**Location**:
- **Metaphysis** of long bones (75%)
- **Distal femur** (40%), **proximal tibia** (20%), **proximal humerus** (10%)
- "Knee region" (60%)
- Flat bones in elderly (pelvis, skull)

**Gross**:
- Destructive mass
- Cortical breakthrough
- Soft tissue extension
- Hemorrhage, necrosis

**Microscopic**:
- **Malignant osteoid production** (diagnostic feature)
- Atypical, pleomorphic cells
- Osteoid (pink, amorphous matrix) produced by tumor cells
- High mitotic rate

**Subtypes**:
- **Conventional (osteoblastic)**: Most common, produces abundant osteoid/bone
- **Chondroblastic**: Cartilage differentiation
- **Fibroblastic**: Spindle cells, minimal osteoid
- **Telangiectatic**: Blood-filled cystic spaces, mimics aneurysmal bone cyst
- **Small cell**: Mimics Ewing sarcoma
- **Parosteal**: Surface, low-grade, better prognosis
- **Periosteal**: Surface, intermediate grade

**Imaging**:
- **X-ray**:
  - Mixed lytic and sclerotic ("sunburst" pattern from periosteal reaction)
  - **Codman triangle**: Elevated periosteum at tumor edge
  - Soft tissue mass
- **MRI**: Define extent, soft tissue involvement
- **CT chest**: Detect pulmonary metastases

**Molecular**: Complex karyotype, RB1, TP53 mutations

**Metastases**:
- **Lungs** (most common, 80%)
- Bone (10%)
- Hematogenous spread

**Clinical**:
- **Pain and swelling** near joint
- Pathologic fracture (10%)
- Elevated alkaline phosphatase (50%)

**Treatment**:
- **Neoadjuvant chemotherapy**: MAP (methotrexate, doxorubicin, cisplatin)
- **Surgical resection**: Limb salvage (90%) or amputation
- **Adjuvant chemotherapy**
- Degree of necrosis after chemotherapy is prognostic (>90% good)

**Prognosis**:
- **Localized disease**: 60-70% 5-year survival
- **Metastatic disease**: 20-30% 5-year survival
- Poor prognostic factors: Metastases, axial location, large size, poor response to chemotherapy

#### Ewing Sarcoma

**Small round blue cell tumor** of bone (also soft tissue)

**Epidemiology**:
- **Second most common** bone malignancy in children/adolescents
- Peak age: 10-20 years
- Caucasians >> African Americans
- Males > females

**Genetics**:
- **t(11;22)(q24;q12)**: 85% of cases
  - **EWSR1-FLI1 fusion** (EWS gene on 22q12, FLI1 on 11q24)
- Other EWS fusions: EWSR1-ERG (10%)
- Diagnostic (pathognomonic)

**Pathology**:

**Location**:
- **Diaphysis** of long bones (femur, tibia, humerus)
- Flat bones (pelvis, ribs, scapula) - 50%
- Extraskeletal (soft tissue) - 10-15%

**Gross**:
- Soft, gray-white mass
- Permeative growth
- Onion-skin periosteal reaction (concentric layers)

**Microscopic**:
- **Sheets of small, round, blue cells**
- Uniform cells, scant cytoplasm
- Round nuclei, fine chromatin
- High nuclear:cytoplasmic ratio
- **Glycogen-rich cytoplasm** (PAS-positive, diastase-sensitive)
- Homer Wright rosettes (rare)

**Immunohistochemistry**:
- **CD99 (MIC2)**: Diffuse membranous staining (highly sensitive, not specific)
- FLI1 positive (nuclear)
- Negative for lymphoid, myeloid, melanoma markers

**Molecular**: EWSR1 rearrangement (FISH or RT-PCR)

**Clinical**:
- **Pain and swelling**
- Fever, weight loss, elevated ESR (mimics infection)
- **Soft tissue mass** (extends beyond bone)

**Metastases**:
- Lungs, bone, bone marrow
- Present in 25% at diagnosis

**Treatment**:
- **Chemotherapy**: Vincristine, doxorubicin, cyclophosphamide (VDC) alternating with ifosfamide, etoposide (IE)
- **Local control**: Surgery and/or radiation
- Radiosensitive tumor

**Prognosis**:
- **Localized disease**: 70% 5-year survival
- **Metastatic disease**: 20-30% 5-year survival
- Poor prognostic factors: Metastases, axial location, large size, poor response to chemotherapy

#### Chondrosarcoma

**Malignant cartilage-producing tumor**

**Epidemiology**:
- **Most common in adults >40 years** (peak 40-60)
- Men > women

**Classification**:
- **Primary**: De novo (90%)
- **Secondary**: From benign precursor (osteochondroma, enchondroma) (10%)

**Pathology**:

**Location**:
- **Pelvis** (30%), **femur**, **ribs**, **shoulder girdle**
- Central (medullary) or peripheral (surface)

**Gross**:
- Lobulated, gray-blue, translucent (cartilage)
- Calcifications (punctate, "rings and arcs")

**Microscopic**:
- **Malignant cartilage**: Atypical chondrocytes in lacunae
- Hypercellularity, binucleated cells
- Myxoid matrix
- **Grading** (1-3): Based on cellularity, atypia, mitoses
  - Grade 1: Low-grade, well-differentiated
  - Grade 2: Intermediate
  - Grade 3: High-grade, dedifferentiated

**Imaging**:
- Lytic lesion with "rings and arcs" calcification
- Endosteal scalloping

**Clinical**:
- **Pain and swelling** (insidious onset)
- Slow growing (grade 1)

**Metastases**:
- **Lungs** (hematogenous)
- Low-grade: Rarely metastasize
- High-grade: 40-50% metastasize

**Treatment**:
- **Wide surgical resection** (primary treatment)
- **Chemo- and radiation-resistant** (unlike osteosarcoma, Ewing)

**Prognosis**:
- **Grade-dependent**:
  - Grade 1: >90% 5-year survival
  - Grade 2: 60-70%
  - Grade 3: 30-40%
- Size, location also affect prognosis

### Metastatic Bone Disease

**Most common malignant bone tumor** (by far)

**Common primary sites**:
- **Breast, prostate** (most common)
- **Lung, kidney, thyroid**
- Mnemonic: **"BLT & Kosher Pickle"** (Breast, Lung, Thyroid, Kidney, Prostate)

**Location**:
- **Axial skeleton** (spine, pelvis, ribs, skull) >> appendicular
- Red marrow distribution (hematogenous spread)

**Types**:

**Osteolytic**:
- Bone destruction, resorption
- Lung, kidney, thyroid, melanoma, multiple myeloma
- Mechanism: Tumor cells secrete factors (PTHrP, IL-1, TNF) → osteoclast activation

**Osteoblastic** (sclerotic):
- Increased bone formation
- **Prostate** (classic), breast (mixed)
- Mechanism: Tumor cells secrete factors (ET-1, BMPs) → osteoblast activation
- Dense, white bone on X-ray

**Mixed**: Breast

**Clinical**:
- **Bone pain** (most common)
- **Pathologic fractures** (low-energy trauma)
- **Hypercalcemia** (osteolytic) - "stones, bones, groans, psychiatric overtones"
- **Spinal cord compression** (spine metastases)

**Diagnosis**:
- **Bone scan**: Technetium-99m (detects osteoblastic activity, very sensitive)
- **PET/CT**: Fluorodeoxyglucose (FDG)
- **X-ray, CT, MRI**: Characterize lesions
- **Biopsy**: If primary unknown

**Treatment**:
- **Treat primary tumor**
- **Bisphosphonates or denosumab**: Reduce skeletal-related events
- **Radiation**: Palliative (pain, prevent fracture, spinal cord compression)
- **Surgery**: Stabilization (impending or pathologic fracture), decompression (spinal cord)
- **Systemic therapy**: Chemotherapy, hormonal (prostate, breast), targeted

## Muscle Pathology

### Muscular Dystrophies

#### Duchenne Muscular Dystrophy (DMD)

**Most common and severe muscular dystrophy**

**Genetics**:
- **X-linked recessive** (Xp21.2)
- **Dystrophin gene** (largest known human gene)
- **Frameshift or nonsense mutations** → Absent dystrophin protein
- 1/3 are new mutations

**Epidemiology**:
- Males affected (1 in 3,500 male births)
- Female carriers usually asymptomatic (X-inactivation)

**Pathogenesis**:
- **Dystrophin**: Links actin cytoskeleton to extracellular matrix (via dystroglycan complex)
- Absence → sarcolemmal instability
- Muscle fiber damage with contraction
- Cycles of degeneration and regeneration
- Eventually: Fibrosis and fatty replacement

**Pathology**:

**Gross**:
- Muscle atrophy (late)
- Pseudohypertrophy (calves): Replacement by fat and connective tissue

**Microscopic**:
- **Variation in fiber size**: Atrophic and hypertrophic fibers
- **Degeneration and necrosis**: Hypercontracted, hyalinized fibers
- **Regeneration**: Basophilic fibers with large nuclei, prominent nucleoli
- **Endomysial fibrosis** (progressive)
- **Fatty replacement**
- Inflammatory cells (macrophages)

**Immunohistochemistry**:
- **Dystrophin absent** (diagnostic)

#### Clinical Features
- **Onset**: 3-5 years
- **Progressive proximal weakness**:
  - Lower extremities first
  - Difficulty running, climbing stairs
  - **Gowers' sign**: Uses hands to "walk up" legs to stand (proximal weakness)
- **Calf pseudohypertrophy**
- **Gait abnormalities**: Waddling gait, toe-walking
- **Loss of ambulation**: By age 12 (wheelchair-bound)
- **Respiratory failure**: Late teens to 20s (most common cause of death)
- **Cardiomyopathy**: Dilated cardiomyopathy (90%)
- **Cognitive impairment**: 30% (dystrophin in brain)

**Laboratory**:
- **Markedly elevated creatine kinase** (CK): 50-100× normal (muscle damage)
- Elevated ALT, AST (from muscle, not liver)

**Diagnosis**:
- Clinical features
- Elevated CK
- **Genetic testing**: Dystrophin gene mutations (preferred)
- **Muscle biopsy**: Absent dystrophin (if genetic testing inconclusive)
- EMG: Myopathic pattern

**Treatment**:
- **Glucocorticoids** (prednisone, deflazacort): Slow progression, prolong ambulation (2-3 years)
- **Eteplirsen**: Exon-skipping for specific mutations (limited efficacy)
- **Gene therapy**: Emerging (microdystrophin delivery)
- **Supportive**:
  - Physical therapy, orthopedic interventions (scoliosis)
  - Respiratory support (BiPAP, tracheostomy)
  - Cardiac management (ACE inhibitors, β-blockers)

**Prognosis**:
- **Life expectancy**: Late 20s to 30s (with supportive care)
- Death from respiratory or cardiac failure

#### Becker Muscular Dystrophy (BMD)

**Milder allelic variant of DMD**

**Genetics**:
- **X-linked recessive**
- **Dystrophin gene**
- **In-frame deletions** → Reduced or truncated (but partially functional) dystrophin

**Clinical**:
- **Onset**: Late childhood to adolescence (later than DMD)
- **Milder, slower progression**
- **Ambulation preserved** into adulthood (40s-50s)
- Cardiomyopathy (30-40%)
- **Life expectancy**: 40s-50s or longer

**Pathology**:
- Similar to DMD but milder
- **Dystrophin present but reduced** (immunohistochemistry)

**CK**: Elevated but less than DMD

**Treatment**: Similar to DMD, supportive

### Myasthenia Gravis

**Autoimmune disorder of neuromuscular junction**

**Epidemiology**:
- Bimodal: Young women (20-30s), older men (60-70s)
- Women > men (early onset)

**Pathogenesis**:
- **Autoantibodies against acetylcholine receptors (AChR)** (85%)
- **Antibodies against MuSK** (muscle-specific kinase) (5%)
- Antibodies bind AChR → receptor degradation, complement-mediated destruction
- Decreased AChRs at postsynaptic membrane
- Impaired neuromuscular transmission

**Association**:
- **Thymic abnormalities** (75%):
  - **Thymic hyperplasia** (60%): Young women
  - **Thymoma** (15%): Older patients
- Other autoimmune diseases (thyroid, lupus, RA)

**Pathology**:
- **Muscle biopsy**: Usually normal or minimal type II fiber atrophy
- **Thymus**: Hyperplasia or thymoma

**Clinical**:
- **Fluctuating muscle weakness**: Worse with use, improves with rest
- **Ocular muscles** (most common, 85%):
  - **Ptosis** (drooping eyelid)
  - **Diplopia** (double vision)
- **Bulbar muscles** (50%):
  - Dysarthria (speech)
  - Dysphagia (swallowing)
  - Facial weakness
- **Limb weakness**: Proximal > distal
- **Respiratory muscles**: Myasthenic crisis (life-threatening)
- **No sensory symptoms**
- Symptoms worsen throughout day

**Diagnosis**:
- **Anti-AChR antibodies**: Positive in 85% (diagnostic)
- **Anti-MuSK antibodies**: If AChR-negative
- **Edrophonium (Tensilon) test**: Short-acting AChE inhibitor, improves symptoms (historical)
- **Ice pack test**: Apply ice to ptotic eye, improves ptosis
- **Repetitive nerve stimulation (EMG)**: Decremental response (>10% decrement)

**Treatment**:
- **Acetylcholinesterase inhibitors**: Pyridostigmine (symptomatic relief)
- **Immunosuppression**:
  - **Glucocorticoids**: Prednisone
  - **Azathioprine, mycophenolate, cyclosporine**
- **Thymectomy**: Especially if thymoma, benefit in non-thymoma patients
- **Plasmapheresis, IVIG**: Myasthenic crisis, pre-surgery
- **Rituximab**: Refractory cases
- **Eculizumab**: Complement inhibitor (C5 inhibitor), for refractory generalized MG

**Myasthenic crisis**:
- Respiratory failure from weakness
- Triggered by infection, surgery, medications
- Requires mechanical ventilation, plasmapheresis/IVIG

**Prognosis**:
- Chronic, fluctuating course
- Good control with treatment in most
- Mortality low with modern treatment

## Key Points

### Metabolic Bone Diseases
- Osteoporosis: Decreased bone mass, T-score ≤-2.5, fragility fractures, bisphosphonates first-line
- Osteomalacia/rickets: Defective mineralization, vitamin D deficiency, elevated ALP, wide osteoid seams
- Paget's disease: Excessive remodeling, mosaic pattern, markedly elevated ALP, bisphosphonates

### Arthropathies
- Rheumatoid arthritis: Symmetric polyarthritis, erosions, RF/anti-CCP, TNF inhibitors
- Seronegative spondyloarthropathies: HLA-B27, axial arthritis, enthesitis, uveitis
- Gout: MSU crystals (needle-shaped, negative birefringence), first MTP, NSAIDs/colchicine, allopurinol
- Pseudogout: CPPD crystals (rhomboid, positive birefringence), chondrocalcinosis, knee
- Osteoarthritis: Most common joint disease, DIP involvement, osteophytes, no DMARDs

### Bone Tumors
- Osteosarcoma: Most common primary bone malignancy, adolescents, metaphysis, malignant osteoid, MAP chemo
- Ewing sarcoma: Small round blue cells, EWSR1-FLI1 fusion, CD99+, radiosensitive
- Chondrosarcoma: Adults, pelvis, chemo/radiation-resistant, wide resection
- Metastases: Most common malignant bone tumor, axial skeleton, breast/prostate most common primaries

### Muscle Diseases
- DMD: X-linked, absent dystrophin, Gowers' sign, wheelchair by age 12, life expectancy 20s-30s
- BMD: Milder, reduced dystrophin, later onset, ambulation preserved
- Myasthenia gravis: Anti-AChR antibodies, fluctuating weakness, ptosis/diplopia, AChE inhibitors, thymectomy

## References

1. Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2021. Chapter 26: Bones, Joints, and Soft Tissue Tumors.

2. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. WHO Classification of Tumours Series. 5th ed. Vol 3. IARC; 2020.

3. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.

4. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.

5. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet. 2008;372(9633):155-163.

6. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32.

7. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760.

8. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162.

9. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: Current scenario and unmet need. World J Orthop. 2016;7(9):527-538.

10. Darras BT, Jones HR Jr, Ryan MM, De Vivo DC. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. 2nd ed. Academic Press; 2014.
